21 day trial into the weight reduction effects of supplementation with 1g and 500mg SolaThin.

Phase 2

Completed

• Conditions: weight and appetite in overweight and obese individuals; Diet and Nutrition - Obesity; Alternative and Complementary Medicine - Herbal remedies

• Registration Number: ACTRN12612000198820
• Lead Sponsor: CYVEX NUTRITION, INC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-16
• Study Completion: 2012-12-19
• Last Update Posted: 16 February 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Participants who meet the following eligibility criteria will be recruited in the trial:
1.Males and females aged 18-40 with Body Mass Index (BMI) >30, otherwise healthy.
2.Are comfortable with computers and willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol.
3.Are comfortable with taking a daily supplement of SolaThin or Placebo for 21 days.
4.Provide a personally signed and dated informed consent indicating that the participant has been informed of all pertinent aspects of the trial.

Exclusion Criteria

Participants presenting with any of the following will not be included in the trial:

1.History of anxiety, depression, psychiatric disorders.
2.History of / do not currently suffer from heart disease or high blood pressure or diabetes
3.Taking any medication, herbal extracts, vitamin supplements or illicit drugs for 4 weeks prior to (and duration of) study
4.Taking any form of medication within 5 days of admission (except for prophylactic antibiotics, or other routine medications to treat benign conditions, such as antibiotics to treat acne) and agree not to take any medication throughout the study
5.Health conditions that would affect food metabolism including the following: food allergies, kidney disease, liver disease and/or gastrointestinal diseases (e.g. Irritable bowel syndrome, coeliac disease, peptic ulcers)
6.Renal function problems, Hypercalcaemia; Hypermagnesemia, Severe hypercalciuria, phenylketonuria (autosomal metabolic disorder),
7.Currently pregnant or lactating

Study & Design

• Study Type: Interventional
• Study Design: Not specified